BioBehavioral Diagnostic Co. (BioBDx), a developer of testing devices for attention-deficit/hyperactivity disorder (ADHD), has raised $5.1 million in a round of venture capital, according to a new filing by the company with the Securities and Exchange Commission. Five separate investors participated in the offering.

The firm's Quotient ADHD System accurately measures motion and analyzes shifts in attention state to give a clear picture of the core symptom areas of ADHD (also known as ADD) even in the presence of conditions other than ADHD. The Quotient ADHD Test report should be interpreted only by qualified professionals in conjunction with other clinical information.